KR101451439B1 - 신경변성 질환의 치료 - Google Patents

신경변성 질환의 치료 Download PDF

Info

Publication number
KR101451439B1
KR101451439B1 KR1020087026561A KR20087026561A KR101451439B1 KR 101451439 B1 KR101451439 B1 KR 101451439B1 KR 1020087026561 A KR1020087026561 A KR 1020087026561A KR 20087026561 A KR20087026561 A KR 20087026561A KR 101451439 B1 KR101451439 B1 KR 101451439B1
Authority
KR
South Korea
Prior art keywords
selenate
disease
pharmaceutical composition
tau
pp2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087026561A
Other languages
English (en)
Korean (ko)
Other versions
KR20090015038A (ko
Inventor
크리스토퍼 호벤스
니알 코르코란
Original Assignee
벨라코르 테라퓨틱스 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벨라코르 테라퓨틱스 피티와이 엘티디 filed Critical 벨라코르 테라퓨틱스 피티와이 엘티디
Publication of KR20090015038A publication Critical patent/KR20090015038A/ko
Application granted granted Critical
Publication of KR101451439B1 publication Critical patent/KR101451439B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020087026561A 2006-03-29 2007-03-29 신경변성 질환의 치료 Expired - Fee Related KR101451439B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78724006P 2006-03-29 2006-03-29
US60/787,240 2006-03-29
PCT/AU2007/000391 WO2007109851A1 (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
KR20090015038A KR20090015038A (ko) 2009-02-11
KR101451439B1 true KR101451439B1 (ko) 2014-10-16

Family

ID=38540722

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087026561A Expired - Fee Related KR101451439B1 (ko) 2006-03-29 2007-03-29 신경변성 질환의 치료

Country Status (14)

Country Link
US (2) US8920851B2 (https=)
EP (1) EP2004204B1 (https=)
JP (1) JP5542430B2 (https=)
KR (1) KR101451439B1 (https=)
CN (1) CN101478977B (https=)
AU (1) AU2007231547B2 (https=)
BR (1) BRPI0709033A2 (https=)
CA (1) CA2644441C (https=)
DK (1) DK2004204T3 (https=)
ES (1) ES2394348T3 (https=)
MX (1) MX2008012479A (https=)
NZ (2) NZ571835A (https=)
RU (1) RU2489155C2 (https=)
WO (1) WO2007109851A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE024953T2 (en) 2004-08-23 2016-02-29 Yeda Res & Dev Peptide inhibitors to mediate stress responses
ES2394348T3 (es) 2006-03-29 2013-01-30 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas con selenato
EP2012806A4 (en) * 2006-04-24 2010-07-28 Alltech Inc METHOD AND COMPOSITIONS FOR MODIFYING CELL FUNCTIONS
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis
WO2009043116A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Methods and compositions for the treatment of phosphatase- related disorders
EP2219649A2 (en) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
JP5328244B2 (ja) * 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2715350B1 (en) 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2016150403A1 (en) 2015-03-26 2016-09-29 Fujian Tiantai Medical Technology Co. Ltd Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
WO2019216589A1 (ko) * 2018-05-09 2019-11-14 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
BR112020026456A2 (pt) * 2018-06-29 2021-03-23 Rejuvenate Biomed Combinação farmacêutica para o uso em doenças relacionadas com a idade e/ou degenerativas
JP7518852B2 (ja) 2019-03-26 2024-07-18 シアー， インコーポレイテッド 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用
WO2023029210A1 (zh) * 2021-08-31 2023-03-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
WO2023057422A1 (en) * 2021-10-06 2023-04-13 Bayer Aktiengesellschaft Universal buffer in methods for safe and rapid detection of pathogen infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62185018A (ja) * 1986-01-27 1987-08-13 スコシア・ホールディングス・ピ．エル．シィ 医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04247033A (ja) 1991-02-04 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 神経細胞壊死抑制剤
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
EP0750511B1 (en) 1994-03-16 2003-06-11 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US6524619B2 (en) 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
DE10059886A1 (de) 2000-12-01 2002-06-20 Basf Coatings Ag Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
CN1812977A (zh) 2003-04-30 2006-08-02 药物研发有限责任公司 取代羧酸
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20050142216A1 (en) 2003-12-31 2005-06-30 Rindlesbach Keith A. Method for reversing Alzheimer dementia
TWI319708B (en) 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
ES2394348T3 (es) 2006-03-29 2013-01-30 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas con selenato
CA2644445A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of benign tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62185018A (ja) * 1986-01-27 1987-08-13 スコシア・ホールディングス・ピ．エル．シィ 医薬組成物
EP0234733A1 (en) * 1986-01-27 1987-09-02 Scotia Pharmaceuticals Limited Pharmaceutical compositions

Also Published As

Publication number Publication date
US8920851B2 (en) 2014-12-30
US20090169649A1 (en) 2009-07-02
DK2004204T3 (da) 2013-01-07
NZ596244A (en) 2013-05-31
WO2007109851A1 (en) 2007-10-04
NZ571835A (en) 2011-11-25
AU2007231547A1 (en) 2007-10-04
RU2008142514A (ru) 2010-05-10
CA2644441A1 (en) 2007-10-04
RU2489155C2 (ru) 2013-08-10
EP2004204B1 (en) 2012-09-12
ES2394348T3 (es) 2013-01-30
CA2644441C (en) 2014-09-09
JP2009532340A (ja) 2009-09-10
KR20090015038A (ko) 2009-02-11
EP2004204A4 (en) 2010-06-02
CN101478977B (zh) 2013-03-27
CN101478977A (zh) 2009-07-08
BRPI0709033A2 (pt) 2011-06-21
AU2007231547B2 (en) 2012-07-12
JP5542430B2 (ja) 2014-07-09
EP2004204A1 (en) 2008-12-24
MX2008012479A (es) 2009-08-13
US20140141104A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
KR101451439B1 (ko) 신경변성 질환의 치료
Lee et al. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury
Hu et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals
De La Mora et al. Distribution of dopamine D2-like receptors in the rat amygdala and their role in the modulation of unconditioned fear and anxiety
Schober et al. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action
JP5616631B2 (ja) 細胞機能を変化させるための方法および組成物
Lee et al. Neuroprotection of ischemic preconditioning is mediated by thioredoxin 2 in the hippocampal CA1 region following a subsequent transient cerebral ischemia
Cai et al. Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation
Sepe et al. Expression of Ambra1 in mouse brain during physiological and Alzheimer type aging
US20220195524A1 (en) Methods and compositions for diagnosis and management of neurodegerative diseases
Sharma et al. Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats
Cha et al. Immunocytochemical study on the distribution of nitrotyrosine in the brain of the transgenic mice expressing a human Cu/Zn SOD mutation
US20020028779A1 (en) Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
Lim et al. The insect molting hormone 20-hydroxyecdysone protects dopaminergic neurons against MPTP-induced neurotoxicity in a mouse model of Parkinson's disease
Jia et al. Mitochondrial bioenergetics stimulates autophagy for pathological MAPT/Tau clearance in tauopathy neurons
Bignante et al. APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models
Li et al. Gastrodin Ameliorates Tau Pathology and BBB Dysfunction in 3xTg‐AD Transgenic Mice by Regulating the ADRA1/NF‐κB/NLRP3 Pathway to Reduce Neuroinflammation
TWI814760B (zh) 脂質運載蛋白型前列腺素ｄ２合成酵素產生促進劑
Jia et al. Mitochondrial bioenergetics stimulates autophagy for pathological tau clearance in tauopathy neurons
Park et al. Protective effects of phosphodiesterase 5 inhibitor, mirodenafil, on traumatic brain injury-induced neuron death
Chen et al. Effect of the beta secretase-1 inhibitor on the amyloid C-terminal fragment of amyloid precursor protein processing in a hyperphosphorylated tau rat model
Sasuclark From Selenium to Synapse: Understanding the Impact of Selenium Deficiency on Parvalbumin Interneurons and Perineuronal Nets in Cortical Cultures
Miner The Multipurpose DNA Repair/Redox Protein APE1 in Rodent and Human Lewy Body Disease
Zhang et al. Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the Alzheimer's disease mouse model by regulating the expression of App secretases
Moreno Rodríguez Learning and memory improvement mediated by CB1 cannabinoid receptors in animal models of cholinergic dysfunction

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171009

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171009